Vericel Stock Sees RS Rating Shoot Higher The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Smaller Cap Biotechs Are In Season: How Are We Doing? SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Trading SMID Biotech Stocks In A Volatile Market Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
The 3 Highest-Rated Medical Stocks You Can Buy Today Are you looking for highly-rated medical stocks? These three contenders are offering substantial growth over the long term.
VCEL Stock Earnings: Vericel Beats EPS, Beats Revenue for Q1 2024 VCEL stock results show that Vericel beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Earnings Scheduled For February 29, 2024 Companies Reporting Before The Bell • Frontline (
NYSE:FRO ) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
3 Top Pharma Stocks for Investors Betting on a Biotech Boom Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.
3 Biotech Stocks That Could Boom or Bust by 2025 Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.
